Physician profile
Jeffrey I Gorwit
NPI 1891798658
$3,206.96
in general payments reported to CMS, 2019-2025
26 companies · $767 in 2025
The $767 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $312 · 2020: $150 · 2021: $448 · 2022: $335 · 2023: $814 · 2024: $381 · 2025: $767.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,962.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,961.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $392.74 | 2022-2023 | Amvia Edge, Biomonitor |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $389.25 | 2019-2025 | Lifevest |
| Shockwave Medical, INC | $365.49 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $356.08 | 2022-2025 | |
| Abbott Laboratories | $262.37 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Medtronic Vascular, INC. | $238.51 | 2019-2020 | |
| Pfizer INC. | $170.08 | 2023-2025 | |
| Amgen INC. | $130.69 | 2023-2025 | Repatha |
| Genzyme Corporation | $125.00 | 2019 | |
| Baxter Healthcare | $111.27 | 2023-2024 | Hillrom - Cardiac Ambulatory Monitor |
| Janssen Pharmaceuticals, INC | $86.38 | 2019-2024 | Xarelto |
| Actelion Pharmaceuticals US, INC. | $70.04 | 2021-2022 | |
| Philips North America LLC | $67.70 | 2023-2024 | (Ck4) Mcot |
| Astrazeneca Pharmaceuticals LP | $58.52 | 2023-2024 | Farxiga, Wainua |
| Merck Sharp & Dohme LLC | $47.89 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $44.12 | 2025 | Onyx Frontier |
| Edwards Lifesciences Corporation | $43.14 | 2021 | |
| Abiomed | $41.11 | 2024-2025 | Impella |
| Kiniksa Pharmaceuticals, LTD. | $39.67 | 2023 | Arcalyst |
| E.R. Squibb & Sons, L.L.C. | $32.23 | 2022-2023 | Camzyos |
| Kestra Medical Technology Services, INC. | $27.83 | 2025 | Assure Wcd |
| Boston Scientific Corporation | $25.15 | 2022 | |
| Chiesi USA, INC. | $21.36 | 2024 | Kengreal |
| Irhythm Technologies, INC. | $21.35 | 2024 | Zio Monitor, Zio Xt Patch |
| Kiniksa Pharmaceuticals International, Plc | $19.72 | 2024 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $19.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Gorwit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.